The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
Open accessAbstract
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm accounting for ∼15% of all leukemia. Progress of the disease from an indolent chronic phase to the more aggressive accelerated phase or blast phase (BP) occurs in a minority of cases and is associated with an accumulation of somatic mutations. We performed genetic profiling of 85 samples and transcriptome profiling of 12 samples from 59 CML patients. We identified recurrent somatic mutations in ABL1 (37%), ASXL1 (26%), RUNX1 (16%), and BCOR (16%) in the BP and observed that mutation signatures in the BP resembled those of acute myeloid leukemia (AML). We found that mutation load differed between the indolent and aggressive phases and that nonoptimal responders had more nonsilent mutations than did optimal responders at the time of diagnosis, as well as in follow-up. Using RNA sequencing, we identified other than BCR-ABL1 cancer-associated hybrid genes in 6 of the 7 BP samples. Uncovered expression alterations were in turn associated with mechanisms and pathways that could be targeted in CML management and by which somatic alterations may emerge in CML. Last, we showed the value of genetic data in CML management in a personalized medicine setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As discussed above somatic mutations in genes other than BCR::ABL1 are not uncommon in CML, particularly in advanced phase disease [33].”
From 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia (2025) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · cited 1×
“CML diagnosis and progression were defined according to World Health Organization criteria for myeloid neoplasms.(21) All control samples were collected by HUH.”
MethodSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667 · cited 1×
“Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by a reciprocal translocation between the long arms of chromosomes 9 and 22 that generates a hybrid gene between breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (ABL1).(1) The disease occurs w…”
BackgroundWang, K., Yuen, S. T., Xu, J., Lee, S. P., Yan, H. H. N., Shi, S. T., Siu, H. C., Deng, S., Chu, K. M., Law, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2983 · Cited by 1,045 · cited 1×
“P24fs) is supported by several observations in a cancer knowledge base (Catalog of Somatic Mutations in Cancer #COSM21288).(40) Other cancer drivers with mutations, although in solitary cases, in AP/BP cases were RERE(41) and SETD2.”
BackgroundBower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T. M.-L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2866 · Cited by 904
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Ma, X., Liu, Y., Liu, Y., Alexandrov, L. B., Edmonson, M. N., Gawad, C., Zhou, X., Li, Y., Rusch, M. C., Easton, J., et al. (2018) · Nature · doi:10.1038/nature25795 · Cited by 901 · cited 2×
“The UV-related signature 7 has been described in pediatric B-ALL.37 CP patients with optimal response showed dominance of mismatch-repair signatures.”
BackgroundEichhorst, B., Robak, T., Montserrat, E., Ghia, P., Hillmen, P., Hallek, M., & Buske, C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv303 · Cited by 612
Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells
Ezhkova, E., Pasolli, H. A., Parker, J. S., Stokes, N., Su, I.-H., Hannon, G., Tarakhovsky, A., & Fuchs, E. (2009) · Cell · doi:10.1016/j.cell.2008.12.043 · Cited by 604
The landscape and therapeutic relevance of cancer-associated transcript fusions
Yoshihara, K., Wang, Q., Torres-Garcia, W., Zheng, S., Vegesna, R., Kim, H., & Verhaak, R. G. W. (2015) · Oncogene · doi:10.1038/onc.2014.406 · Cited by 450 · cited 1×
“Other potentially oncogenic hybrids included DSCC1-TAF2 identified in breast cancer and RSL24D1-RAB27A detected in lung adenocarcinoma.(54) The TMEM236-MRC1 hybrid was found in 2 cases, being the only recurrent hybrid other than BCR-ABL1.”
BackgroundGiustacchini, A., Thongjuea, S., Barkas, N., Woll, P. S., Povinelli, B. J., Booth, C. A. G., Sopp, P., Norfo, R., Rodriguez-Meira, A., Ashley, N., et al. (2017) · Nature Medicine · doi:10.1038/nm.4336 · Cited by 403 · cited 1×
“R177K at diagnosis progressed into BP at 7 months.(43) We also detected variants in epigenetic modifiers.”
BackgroundSelf-citation
Research works printed but not linked: 2
- Mancini, 2017, SETD2 Loss of Function Is a Recurrent Event in Advanced-Phase Chronic Myeloid Leukemia [abstract], Blood, 130, Abstract 43
- Baer, 2017, Mutation Screening at Diagnosis Reveals a High Frequency of ASXL1 Mutations in CML Patients Who Fail to Achieve Molecular Remission Criteria after One Year of TKI Treatment [abstract], Blood, 130, Abstract 1585
Cited by
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., DeAngelo, D. J., Gotlib, J., Hobbs, G., Maness, L., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0047 · Cited by 262
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shah, N. P., Bhatia, R., Altman, J. K., Amaya, M. L., Begna, K. H., Berman, E., Chan, O., Clements, J., Collins, R. H., Curtin, P. T., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0007 · Cited by 194
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Apperley, J. F., Milojkovic, D., Cross, N. C. P., Hjorth-Hansen, H., Hochhaus, A., Kantarjian, H., Lipton, J. H., Malhotra, H., Niederwieser, D., Radich, J., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02664-w · Cited by 226
“As discussed above somatic mutations in genes other than BCR::ABL1 are not uncommon in CML, particularly in advanced phase disease [33].”
Cross, N. C. P., Ernst, T., Branford, S., Cayuela, J.-M., Deininger, M., Fabarius, A., Kim, D. D. H., Machova Polakova, K., Radich, J. P., Hehlmann, R., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02048-y · Cited by 120
“Nevertheless, some studies have found that ASXL1 mutations [55, 56] or overall somatic mutation burden [57] prior to treatment are associated with poor outcomes.”
BackgroundOchi, Y., Yoshida, K., Huang, Y., Kuo, M., Nannya, Y., Sasaki, K., Mitani, K., Hosoya, N., Hiramoto, N., Ishikawa, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23097-w · Cited by 94
Metadata
- Authors
- Adnan Awad, S., Kankainen, M., Ojala, T., Koskenvesa, P., Eldfors, S., Ghimire, B., Kumar, A., Kytölä, S., Kamel, M. M., Heckman, C. A., Porkka, K., & Mustjoki, S.
- Affiliations
- Hematology Research Unit Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;
- University of Helsinki (FI)
- Department of Pharmacology, Faculty of Medicine, and
- Helsinki University Hospital (FI)
- Cairo University (EG)
- Corresponding author
- Kankainen, Matti
- ORCID
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2020-02-11
- Volume
- 4
- Issue
- 3
- Pages
- 546-559
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC7013270
- OpenAlex
- W3005797317
- Cited by
- 67
- References
- 69
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 12 · 2023: 10 · 2022: 11 · 2021: 13 · 2020: 5
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion)
- Funders
- Finnish Cancer Institute
- Incyte
- Academy of Finland (287224, 292605 and 287224, 292605)
- Suomen Kulttuurirahasto
- Tekes (Dnro 6113/31/2016, 6113/31/2016)
- Signe ja Ane Gyllenbergin Säätiö
- China Scholarship Council
- Syöpäjärjestöt
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- chronic myeloid leukemia, somatic mutations, mutation accumulation, blast crisis, c-Abl, ASXL1, RUNX1, BCOR, mutational signatures, acute myeloid leukemia, BCR-ABL1, gene expression profiling, mutational burden, treatment response, personalized medicine
- MeSH terms
- Mutation Accumulation, Blast Crisis, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000943
- The paper
- Adnan Awad, S., Kankainen, M., Ojala, T., Koskenvesa, P., Eldfors, S., Ghimire, B., Kumar, A., Kytölä, S., Kamel, M. M., Heckman, C. A., Porkka, K., & Mustjoki, S. (2020). Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000943
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.